2012
Antidepressants
Bhagwagar Z, Heninger G. Antidepressants. 2012, 1185-1198. DOI: 10.1093/med/9780199696758.003.0153.Peer-Reviewed Original ResearchWorld Health Organization Global BurdenMajor public health problemPharmacology of antidepressantsLargest causeTreatment of depressionMajor depressive disorderPublic health problemAbstract Major depressive disorderImportance of depressionRecurrent illnessDepressive disorderPrimary treatmentAntidepressant drugsGlobal burdenHigh riskHealth problemsDepressionAntidepressantsDrugsPatientsDepressed individualsSelective useCliniciansBurdenDisease
2010
P.1.025 Molecular imaging of beta-2 subunit containing nicotinic acetylcholine receptors in major depressive disorder
Saricicek A, Esterlis I, Ruf B, Maloney K, Muralidharan A, Seibyl J, Tamagnan G, Bois F, Staley J, Bhagwagar Z. P.1.025 Molecular imaging of beta-2 subunit containing nicotinic acetylcholine receptors in major depressive disorder. European Neuropsychopharmacology 2010, 20: s22. DOI: 10.1016/s0924-977x(10)70027-4.Peer-Reviewed Original Research
2009
Enhanced Visual Motion Perception in Major Depressive Disorder
Golomb JD, McDavitt JR, Ruf BM, Chen JI, Saricicek A, Maloney KH, Hu J, Chun MM, Bhagwagar Z. Enhanced Visual Motion Perception in Major Depressive Disorder. Journal Of Neuroscience 2009, 29: 9072-9077. PMID: 19605644, PMCID: PMC2772577, DOI: 10.1523/jneurosci.1003-09.2009.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnalysis of VarianceContrast SensitivityDepressive Disorder, MajorDiscrimination LearningDiscrimination, PsychologicalHumansMotion PerceptionNeuropsychological TestsOrientationPattern Recognition, VisualPhotic StimulationPsychophysicsReaction TimeSensory ThresholdsVisual AcuityYoung AdultConceptsSpatial suppressionMotion perceptionLarge high-contrast stimuliMotion discrimination taskVisual motion perceptionMajor depressive disorderGreater lifetime durationHigh-contrast stimuliPerceptual discriminationHealthy young adultsVisual processingDiscrimination taskTime of testingTrait vulnerabilityPsychophysical performanceCounterintuitive hypothesisEndophenotypic markerVisual systemProcessing tasksMood symptomsOccipital cortexDepressive disorderYoung adultsVisual pathwayCortical level
2008
Nicotinic receptor dysfunction in major depressive disorder: A trait vulnerability marker of depression
Bhagwagar Z, Esterlis I, Ruf B, Muralidharan A, Lorberg B, Saricicek A, Bois F, Tamagnan G, Seibyl J, Staley J. Nicotinic receptor dysfunction in major depressive disorder: A trait vulnerability marker of depression. NeuroImage 2008, 41: t176. DOI: 10.1016/j.neuroimage.2008.04.143.Peer-Reviewed Original Research
2004
Inositol for depressive disorders
Taylor M, Wilder H, Bhagwagar Z, Geddes J. Inositol for depressive disorders. Cochrane Database Of Systematic Reviews 2004, 2004: cd004049. PMID: 15106232, PMCID: PMC6984679, DOI: 10.1002/14651858.cd004049.pub2.Peer-Reviewed Original ResearchConceptsTreatment of depressionCochrane Controlled Trials RegisterControlled Trials RegisterTrials RegisterAdjunctive therapyDepressive disorderNeurosis Controlled Trials RegisterCochrane Collaboration DepressionAcceptability of treatmentDouble-blind designShort-term trialsAntidepressant medicationDATA COLLECTIONTherapeutic benefitAlternative treatmentReference listsAffective disordersEffective interventionsTerm trialsAdverse effectsTrialsPoor acceptabilityDepressionTreatmentDisorders
2003
Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients.
Sharpley A, Bhagwagar Z, Hafizi S, Whale W, Gijsman H, Cowen P. Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. The Journal Of Clinical Psychiatry 2003, 64: 192-6. PMID: 12633128, DOI: 10.4088/jcp.v64n0212.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAntidepressive AgentsAntipsychotic AgentsCross-Over StudiesDepressive DisorderDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansMaleMiddle AgedPersonality InventoryPlacebosPolysomnographyPsychiatric Status Rating ScalesRisperidoneSleep, REMTreatment OutcomeWakefulnessConceptsRapid eye movement (REM) sleepEye movement sleepDepressed patientsHealthy volunteersRisperidone treatmentMovement sleepREM sleepMedication-resistant depressed patientsTreatment-resistant depressed patientsConventional antidepressant medicationAntidepressant-like effectsAntipsychotic agent risperidoneDepression Rating ScaleMajor depressive disorderDSM-IV criteriaPatients meritRisperidone additionRisperidone augmentationAntidepressant medicationRisperidone administrationSingle doseTherapeutic dosesAugmentation agentsDepressive disorderHealthy subjects